echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pfizer's oral JAK inhibitor Xeljanz receives two new indications in the EU

    Pfizer's oral JAK inhibitor Xeljanz receives two new indications in the EU

    • Last Update: 2021-11-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompilationTom Lee

    A few days ago, the European Commission (EC) announced the approval of Pfizer’s JAK inhibitor oral drug Xeljanz (tofacitinib) for the treatment of young children with active polyarticular joints who are two years of age and older who have first used anti-rheumatic drugs (DMARDs) and have poor response to treatment.
    Patients with idiopathic arthritis (JIA) and juvenile psoriatic arthritis (PsA)
    .

    This time the European Union has approved two formulations of Pfizer Xeljanz, including a tablet and a new oral solution (the dosage is determined based on the weight of the patient)
    .


    As the first Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis, Pfizer Xeljanz has previously been awarded in four indications Approval by the European Union


    The active pharmaceutical ingredient of Xeljanz is tofacitinib, which is an oral JAK inhibitor that can selectively inhibit JAK kinase and block the JAK/STAT pathway.
    This signaling pathway is a cytokine-stimulated pathway discovered in recent years.
    The signal transduction pathway is involved in many important biological processes such as cell proliferation, differentiation, apoptosis and immune regulation
    .

    In September 2020, the US FDA approved Pfizer Xeljanz for the treatment of juvenile idiopathic arthritis (pcJIA) in children and adolescents aged 2 years and older with active polyarticular disease
    .


    This approval is mainly based on data from a phase 3 study A3921104


    It is worth noting that Xeljanz was approved for marketing in Mainland China in March 2017 for the treatment of moderate to severely active RA adult patients with insufficient or intolerable MTX treatment
    .


    This approval makes Xeljanz the first JAK inhibitor to treat rheumatoid arthritis (RA) in the Chinese market


    Although the drug has been approved by the European Union again this time, the potential safety issues of JAK inhibitors including Pfizer Xeljanz have always been the focus of attention of various countries
    .


    Previously, the European Medicines Agency's Drug Safety Risk Assessment Committee also issued a safety warning, restricting Pfizer's oral JAK inhibitor Xeljanz, and for patients with a high risk of pulmonary thrombosis, doctors are not allowed to prescribe 10mg twice a day


    Reference source: Xeljanz® (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.